当前位置:首页 - 行情中心 - 科源制药(301281) - 财务分析 - 现金流量表

科源制药

(301281)

  

流通市值:43.37亿  总市值:43.37亿
流通股本:1.08亿   总股本:1.08亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金289,987,235.36175,247,001.4473,885,748.85299,180,405.94
  收到的税费返还---502,727.86
  收到其他与经营活动有关的现金15,099,790.879,966,015.6444,649,924.8239,899,125.35
  经营活动现金流入小计305,087,026.23185,213,017.08118,535,673.67339,582,259.15
  购买商品、接受劳务支付的现金106,139,609.1670,190,818.6431,978,248.4496,777,908.16
  支付给职工以及为职工支付的现金81,257,056.5455,600,999.0926,878,547.69109,436,259.11
  支付的各项税费38,767,185.9218,539,698.213,476,826.5914,707,958.8
  支付其他与经营活动有关的现金24,111,949.3-1,375,670.9325,080,071.7975,191,055.39
  经营活动现金流出小计250,275,800.92142,955,845.0187,413,694.51296,113,181.46
  经营活动产生的现金流量净额54,811,225.3142,257,172.0731,121,979.1643,469,077.69
二、投资活动产生的现金流量:
  收回投资收到的现金369,998,000270,000,000-596,708,619.72
  取得投资收益收到的现金1,554,897.251,431,684.041,200,183.934,617,837.07
  处置固定资产、无形资产和其他长期资产收回的现金净额9,706.393,260.39-500,578.99
  收到的其他与投资活动有关的现金--7,100,000-
  投资活动现金流入小计371,562,603.64271,434,944.438,300,183.93601,827,035.78
  购建固定资产、无形资产和其他长期资产支付的现金58,971,319.3464,876,490.1227,630,358.68137,050,696.11
  投资支付的现金587,050,003.06448,885,902.259,000,000343,322,620.87
  支付其他与投资活动有关的现金---38,011.25
  投资活动现金流出小计646,021,322.4513,762,392.3736,630,358.68480,411,328.23
  投资活动产生的现金流量净额-274,458,718.76-242,327,447.94-28,330,174.75121,415,707.55
三、筹资活动产生的现金流量:
  取得借款收到的现金110,982,103.2893,879,517.6644,398,432.4570,161,627.89
  筹资活动现金流入小计110,982,103.2893,879,517.6644,398,432.4570,161,627.89
  偿还债务支付的现金13,731,129.512,124,719.540,0003,558,384.98
  分配股利、利润或偿付利息支付的现金9,952,563.338,143,231.991,158,514.6224,820,297.38
  筹资活动现金流出小计23,683,692.8320,267,951.491,198,514.6228,378,682.36
  筹资活动产生的现金流量净额87,298,410.4573,611,566.1743,199,917.8341,782,945.53
四、汇率变动对现金及现金等价物的影响-730,371.66-748,311.04-204,929.59453,917.96
五、现金及现金等价物净增加额-133,079,454.66-127,207,020.7445,786,792.65207,121,648.73
  加:期初现金及现金等价物余额298,891,416.94298,891,416.94298,891,416.9491,769,768.21
  期末现金及现金等价物余额165,811,962.28171,684,396.2344,678,209.59298,891,416.94
补充资料:
  净利润-64,470,616.69-16,376,551.12
  资产减值准备--1,920,584.69-19,476,562.68
  固定资产和投资性房地产折旧-22,687,801.11-45,382,820.03
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-22,687,801.11-45,382,820.03
  无形资产摊销-5,015,836.5-6,588,819.94
  长期待摊费用摊销--696,123.96-303,526.17
  处置固定资产、无形资产和其他长期资产的损失----303,640.29
  固定资产报废损失-6,165.68-565,413.44
  公允价值变动损失--163,972.6--
  财务费用-1,206,385.28--437,347.32
  投资损失--307,322.09--5,925,403.13
  递延所得税--2,340,691.75--687,897.25
  其中:递延所得税资产减少--767,984.02--1,204,353.49
    递延所得税负债增加--1,572,707.73-516,456.24
  存货的减少-26,421,773.49--34,262,804.34
  经营性应收项目的减少--153,768,696.96--31,870,729.66
  经营性应付项目的增加-69,371,934.4-28,263,206.3
  其他-12,274,050.97--
  现金的期末余额-171,684,396.2-298,891,416.94
  减:现金的期初余额-298,891,416.94-91,769,768.21
  现金及现金等价物的净增加额--127,207,020.74-207,121,648.73
公告日期2026-10-262026-08-272026-04-242026-04-16
审计意见(境内)标准无保留意见
TOP↑